Early barrett's carcinoma of the esophagus

Annals of Thoracic and Cardiovascular Surgery

Volumn 14, Issue 6, 2008, Pages 347-354

  Hölscher, Arnulf H ^a   Vallböhmer, Daniel ^a   Bollschweiler, Elfriede ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL TRANSFORMATION; DISEASE COURSE; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; MUCOSA; PATHOLOGY; PRECANCER; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MUCOUS MEMBRANE; PRECANCEROUS CONDITIONS; TREATMENT OUTCOME;

EID: 62449167630     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Froelicher P, Miller G. The European experience with esophageal cancer limited to the mucosa and submucosa. Gastrointest Endosc 1986; 32: 88-90.
2. Bollschweiler E, Wolfgarten E, Gutschow C, Hölscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549-55.
3. Parfitt JR, Miladinovic Z, Driman DK. Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada an epidemiological study from 1964-2002. Can J Gastroenterol 2006; 20: 271-6.
4. Hölscher AH, Bollschweiler E, Schneider PM, Siewert JR. Early adenocarcinoma in Barrett's oesophagus. Br J Surg 1997; 84: 1470-3.
5. Bollschweiler E, Baldus SE, Schröder W, Prenzel K, Gutschow C, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy 2006; 38: 149-56.
6. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002; 346: 836-42.
7. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122: 588-90.
8. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal ref lux. Gut 2004; 53: 1070-4.
9. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004; 39: 1175-9.
10. Voutilainen M, Sipponen P, Mecklin JP, Juhola M, Färkkilä M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61: 6-13.
11. Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, et al. Prognostic influence of Barrett's esophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux diseasee (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD Study. Gut 2005; 54: 746-51.
12. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54: 1062-6.
13. Bollschweiler E, Knoppe K, Wolfgarten E, Hölscher AH. Prevalence of reflux symptoms in the general population of cologne. Z Gastroenterol 2007; 45: 177-81.
14. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-17.
15. Bardhan KD, Royston C, Nayyar AK. Reflux rising! An essay on witnessing a disease in evolution. Dig Liver Dis 2006; 38: 163-8.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
17. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002; 360: 1587-9.
18. Whittles CE, Biddlestone LR, Burton A, Barr H, Jankowski JA, et al. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. J Pathol 1999; 187: 535-40.
19. Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998; 115: 1381-6.
20. Vallböhmer D, Peters JH, Oh D, Kuramochi H, Shimizu D, et al. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma. Surgery 2005; 138: 701-7.
21. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998; 83: 652-9.
22. Vallböhmer D, Peters JH, Kuramochi H, Oh D, Yang D, et al. Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg 2006; 141: 476-81.
23. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001; 85: 383-92.
24. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5.
25. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002; 51: 130-1.
26. Rugge M, Cassaro M, Di Mario F, Leo G, Leandro G, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003; 52: 1111-6.
27. Tsukuma H, Oshima O, Narahara H, Morii T. Natural history of early gastric cancer: a non-concurrent, long term follow up study. Gut 2000; 47: 618-21.
28. Gutschow CA, Schröder W, Prenzel K, Bollschweiler E, Romagnoli R, et al. Impact of antireflux surgery on Barrett's esophagus. Langenbecks Arch Surg 2002; 387: 138-45.
29. Chang EY, Morris CD, Seltman AK, O'Rourke RW, Chan BK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg 2007; 246: 11-21.
30. Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Molina J, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barret's esophagus. Ann Surg 2003; 237: 291-8.
31. Liu L, Hofstetter W, Rashid A, Swisher S, Correa A, et al. Significance of the depth of tumor invasion in early (T1) esophageal adenocarcinoma. Mod Pathol 2005; 18: 110A.
32. Westerterp M, Koppert LB, Buskens CJ, Tilanus HW, ten Kate FJ, et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 2005; 446: 497-504.
33. Rice TW. Superficial oesophageal carcinoma: is there a need for three-field lymphadenectomy? Lancet 1999; 354: 792-4.
34. May A, Günter E, Roth F, Gossner L, Stolte M, et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004; 53: 634-40.
35. Shimada H, Nabeya Y, Matsubara H , Okazumi S, Shiratori T, et al. Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg 2006; 191: 250-4.
36. Araki K, Ohno S, Egashira A, Saeki H, Kawaguchi H, et al. Pathologic features of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis. Cancer 2002; 94: 570-5.
37. Endo M, Yoshino K, Kawano T, Nagai K, Inoue H. Clinocopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus 2000; 13: 125-9.
38. Chibana Y, Fujii S, Ichikawa K, Fujita M, Ono Y, et al. Tumor cell dissociation score highly correlates with lymph node metastasis in superficial esophageal carcinoma. J Gastroenterol Hepatolo 2005; 20: 1371-8. (Pubitemid 43960834)
39. Sato Y, Motoyama S, Maruyama K, Okuyama M, Ogawa J. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg 2005; 201: 188-93.
40. van Sandick JW, van Lanschot JJ, ten Kate FJ, Offerhaus GJ, Fockens P, et al. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: implications for therapeutic decision making. Cancer 2000; 88: 2429-37.
41. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001; 234: 520-31.
42. Rice TW, Blackstone EH, Goldblum JR, DeCamp MM, Murthy SC, et al. Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 2001; 122: 1077-90.
43. Stein HJ, Feith M, von Rahden BH, Siewert JR. Approach to early Barret's cancer. World J Surg 2003; 27: 1040-6.
44. Oh DS, Hagen JA, Chandrasoma PT, Dunst CM, Demeester SR, et al. Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus. J Am Coll Surg 2006; 203: 152-61.
45. May A, Gossner L, Behrens A, Kohnen R, Vieth M, et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc 2003; 58: 167-75.
46. Ell C, May A, Gossner L, pech O, Günter E, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118: 670-7.
47. Ell C, May A, Pech O, Gossner L, Gunter E, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65: 3-10.
48. Merendino KA, Dillard DH. The concept of sphincter substitution by an interposed jejunal segment for anatomic and physiologic abnormalities at the esophagogastric junction; with special reference to reflux esophagitis, cardiospasm and esophageal varices. Ann Surg 1955, 142: 486-506.
49. Gutschow CA, Schröder W, Wolfgarten E, Hölscher AH. Merendino procedure with preservation of the vagus for early carcinoma of the gastroesophageal junction. Zentralbl Chir 2004; 129: 276-81.
50. Stein HJ, Feith M, Mueller J, Werner M, Siewert JR. Limited resection for early adenocarcinoma in Barrett's esophagus. An Surg 2000; 232: 733-42.
51. Salo J. Personal Communication 2006.
52. Banki F, Mason RJ, DeMeester SR, Hagen JA, Balaji NS, et al. Vagal-sparing esophagectomy: a more physiologic alternative. Ann Surg 2002; 236: 324-36.
53. Peyre CG, DeMeester SR, Rizzetto C, Bansal N, Tang AL, et al. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and Barrett with high-grade dysplasia. Ann Surg 2007; 246: 665-74.
54. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347: 1662-9.
55. van Sandick JW, van Lanschot JJ, ten Kate FJ, Tijssen JG, Obertop H. Indicators of prognosis after transhiatal esophageal resection without thoracotomy for cancer. J Am Coll Surg 2002; 194: 28-36.
56. Hölscher AH. Endoscopic mucosal resection for early squamous-cell cancer of the esophagus-a dangerous game or standard treatment? Endoscopy 2007; 39: 77-9.